anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIMS/INTRODUCTION: The aim of the present study was to evaluate the status of glycemic control, and assess the effects of the disease course and comprehensive management measures on the blood glucose level in children and adolescents with type 2 diabetes mellitus.
MATERIALS AND METHODS: The study collected the clinical data of type 2 diabetes patients in Beijing Children's Hospital from January 2015 to September 2020. Patients were grouped based on the disease course to compare their glycated hemoglobin (HbA1c) level, islet β-cell function, insulin resistance and comprehensive management measures.
RESULTS: Of the 170 participants, the median disease course was 2.0 years (interquartile range [IQR] 1.0-4.0 years). The baseline HbA1c was 11.2% (IQR 9.2-12.4%). According to the grouping by the disease course, the median HbA1c was the lowest (5.7% [IQR 5.3-6.1%]) in the half-year course group and the highest in the 4-year course group (9.0 [IQR 6.8%-11.3%]). Compared with the group with a disease duration <2 years, patients in the >4 years group had a lower proportion of patients with HbA1c <7% (29.2% vs 66.2%), a lower homeostasis model assessment of β-cell function, and a lower proportion with a controlled diet, moderate-intensity exercise, regular follow up and no drug treatment. We deemed HbA1c as the dependent variable, and found that disease duration, homeostasis model assessment of β-cell function at follow up, continuous moderate-intensity exercise, regular review and treatment regimen were significant influencing factors for glycemic control.
CONCLUSIONS: Children and adolescents with type 2 diabetes and a prolonged disease course showed poor glycemic control and decreased islet β-cell function. A good lifestyle, especially moderate-intensity exercise, can help such cases better control their blood glucose level.
Peptides which include unnatural amino acids and which either inhibit or promote the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount of such peptides that are GnRH antagonists prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads. The antagonists may be used to treat steroid-dependent tumors, such as prostatic and mammary tumors. The peptides are analogs of the decapeptide GnRH wherein there is at least one residue of an unnatural amino acid in the 3-, 5-, 6- and/or 8-positions. Such unnatural amino acids are useful in the synthesis of peptides and have the formula U*:  (* CHEMICAL STRUCTURE *)  where W is (CH2)n or  (* CHEMICAL STRUCTURE *)  n is an integer from 1 to 6; and j=1, 2 or 3. Preferably, either Y is N-CN, X is NH and R2 is alkyl, modified alkyl, alkenyl, alkynyl, aryl or methyl pridyl or  (* CHEMICAL STRUCTURE *)  where R11 is H or acyl.
1. A medical preparation for the treatment and prophylaxis of infectious and inflammatory diseases, comprising benzyldimethyl[3-(myristoilamino)propyl] ammonium chloride and a pharmaceutical diluent, characterized in that contains comprising benzyldimethyl[3-(myristoilamino)propyl]ammonium chloride as monohydrate. 2. The medical preparation according to claim 1, characterized in that contains water and/or alcohol as a pharmaceutical diluent and monohydrate benzyldimethyl[3-(myristoilamino)propyl]ammonium chloride in 0.01-1.0%. 3. The medical preparation according to claim 1, characterized in that contains any base of vegetable, animal or synthetic origin as a pharmaceutical diluent with the following component ratio: vegetable, animal or synthetic baseá99.0-99.9 benzyldimethyl[3-(myristoilamino)propyl]ammonium chloride, monohydrate 1.0-0.01 4. Use a medical preparation according to claims 1-3 for the treatment and prophylaxis of infectious and suppurative inflammatory diseases of different aetiology and localization and a preparation having antiseptic, disinfecting, spermicidal, antiviral and immuno-modulating action.
The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids, which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of nephrotic syndrome (patients >2 years of age), and aggressive lymphomas and leukemias (patients >1 month of age). Other indications for pediatric use of corticosteroids, e.g., severe asthma and wheezing, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations. 

The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see ADVERSE REACTIONS). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose.
Because the barrier function of the skin of the newborn is still immature, disruption of skin integrity is a commonly observed problem. The purpose of the study was to test the applicability and effectiveness of sunflower seed oil (SSO) and Liquid Vaseline (LV) in maintaining skin integrity in term and preterm neonates in the Neonatal Intensive Care Unit (NICU). The sample size of the study has been determined by the power analysis (G\*Power 3.1.9.2), The sample size was found to be a total of 66 neonates including minimum of 22 neonates for each group. It was estimated that case losses may occur and therefore, it was decided to conduct the study with a total of 90 neonates including 30 neonates in three groups. Assignment of neonates to research groups was done according to the order of hospitalization in the NICU. The first hospitalized neonates SSO, the second hospitalized LV, and the third hospitalized were included in the control group. The groups were repeated until they were complete. Weighing the neonate, taking vital signs, evaluating the skin condition, wiping the whole body, and stabilizing the general condition of the neonate before moisturizing the skin were taken into account. Neonates Information Form(NIF) and Neonatal Skin Condition Score (NSCS) were used for data collection. Parents of neonates were informed about the study. First day of hospitalization; Demographic data and medical history of the neonate in the study or control group were obtained from the patient file records. The neonate was weighed, vital signs were taken, and the data were recorded in the NIF.

The body of all neonates in the research or control group was wiped on the 1st day of hospitalization. In the following days, it was repeated 2 times a week (Monday and Friday) in the same way.The skin condition of the neonate in the research or control group was evaluated with the NSCS scale. The first skin evaluation was performed on the 1st day of hospitalization (1st NSCS). Skin condition was re-evaluated at 48 hour intervals in the following days. Skin condition of the neonate in the control or research group was evaluated a total of 9 times with 48-hour intervals. After the initial skin condition assessment, the neonate's skin is moistened with SSO or LV, depending on the group. It was rehydrated once a day (24 hours apart) in the following days.
It has previously been shown that elderly patients show signs of increased perioperative hemostatic activation after coronary artery bypass grafting. In particular, compared to younger patients, elderly patients had more extensive fibrinolysis postoperatively. The antifibrinolytic drug tranexamic acid has been shown to reduce fibrinolysis, bleeding, and the need for transfusions of blood components after various cardiac surgical procedures. In this study we will investigate whether tranexamic acid reduces perioperative activation of coagulation as measured by plasma concentrations of antithrombin, thrombin-antithrombin complex, and prothrombin fragment 1+2, whether tranexamic acid reduces perioperative fibrinolysis as measured by plasma concentrations of D-dimer, and whether tranexamic acid reduces platelet activation as measured by plasma concentrations of neutrophil activating peptide 2 and by flow cytometry in elderly (above 70 years of age) patients undergoing combined aortic valve replacement and coronary artery bypass surgery. The primary endpoint of the study will, however, be total postoperative bleeding and the need for transfusions of blood components during and after surgery. The need for transfusions will be registered during the whole hospital stay. Patients will be randomized into two groups and given either tranexamic acid or placebo (0.9% sodium chloride) as an intravenous bolus injection before start of surgery followed by an intravenous infusion during surgery. Blood samples for the above mentioned plasma concentration measurements will be drawn preoperatively, intraoperatively during CPB, and 30 minutes and 3, 5, and 20 hours postoperatively. Postoperative bleeding will be registered for 16 hours. The need for any transfusions of blood products will be registered for the whole hospital stay.
The intermittent energy restricted group will undergo 3 nonconsecutive days of partial fasting per week. During the 3 days of partial fasting, participants will be asked to consume a very-low calorie diet (VLCD) providing 550kcal/day for women and 650kcal/day for men. The VLCD products provide 110kcal/pack and include a variety of shakes, smoothies and soups. For the feeding days a diet matching energy needs will be prescribed, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
The present invention relates to the management of pain without requiring or allowing for reduction in the level of administration of narcotics, and to self-management of pain on an outpatient basis. Accordingly, the present invention is broadly directed to a method for treating pain in a subject comprising administering via a transmucosal, transdermal, or oral route a dose of ketamine effective to alleviate pain to a subject suffering from pain. The invention is further directed to a method for synergistically treating pain in a subject comprising administering via any route a dose of ketamine effective to allow for reduction in the level of an ongoing pain therapy, or decrease pain (improve the level of pain relief), or both. Transmucosal, transdermal, and oral administration of ketamine advantageously allows for patient self administration of the drug, which provides for pain management on an outpatient basis. Moreover, ketamine administration in transdermal devices (suppositories, candies, buccal patches) is generally socially acceptable. In a specific example, a patient suffering from intractable bladder pain controlled breakthrough pain by transmucosal (nasal) administration of about 16 mg to about 32 mg of ketamine per dose.
In 2020, Bhutan pioneered a school-based gender-neutral human papillomavirus (HPV) vaccination program, achieving an impressive 96% vaccination coverage rate by 2021. This study, conducted through 49 in-depth interviews with community leaders, policymakers, parents, teachers, and health workers, and 12 focus group discussions with boys who received HPV vaccination. We used conventional content analysis to analyze the data. Enablers of the extension of gender-neutral HPV vaccination included social mobilization and advocacy efforts, which encompassed community engagement and leadership and collaborations with schools. Equally crucial were proficient program management and the strategic use of digital interventions. Challenges included tracking and reaching eligible adolescents. Vaccinated boys perceived school-based vaccination to be a key enabler of vaccine update. The study concludes that extending a girls-only HPV vaccination program to gender-neutral is feasible and acceptable in Bhutan. Findings related to challenges and ways for overcoming them can support other countries interested in gender-neutral HPV vaccination program.
CPT is a gold-standard evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms. It can be delivered in group and individual formats, but will be delivered in a group format in this project due to feasibility in the setting. Structure will be based on feedback obtained during completion of Aim 2 while remaining within the range evaluated in prior research (i.e., 8-12 sessions, 1-2x per week, each lasting 1.5-2 hours).
Participants in INTERxVENT will complete a 'Baseline Assessment' and 'Follow-up' questionnaire, and will have a health professional visit his/her home for an initial assessment (BP,height,weight,waist measurement) and blood collection (blood glucose and cholesterol levels). As part of the program, each participant will also complete a self-reported 'Health History Questionnaire' (HHQ); a follow-up HHQ will be completed about 12 weeks into the program to monitor progress. Each participant randomized to INTERxVENT receives educational articles which address diabetes management issues. A structured, individualized program, consisting of educational materials and 12 live mentoring/coaching telephone calls will take place over 6 months. The mentors consist of allied health professionals. The sequence by which educational content is administered will be both self-directed and guided by the mentors using an algorithmic approach according to the participant's readiness-to-change scores.
<P>PROBLEM TO BE SOLVED: To obtain a prophylactic/therapeutic agent for inflammatory diseases or malignant tumors comprising a highly safe and highly effective substance as the active ingredient.  <P>SOLUTION: This prophylactic/therapeutic agent comprises a soluble gp130 or an analog thereof as the active ingredient. By administering this agent, i.e. the soluble gp130 (a molecule of a glycoprotein which is a signal transmitting chain of) IL-6 receptor or an analog thereof capable of being neutralized beforehand, to a conjugated IL-6/soluble IL-6 receptor bindable to the gp130 partly expressed extracellularly, a STAT (signal transducer and activator of transcription)-3-phosphorylation response system is controlled, thus effectively preventing/treating inflammatory intestinal diseases. Whereas, the neutralization activity of the soluble gp130 or the analog thereof hinders an inhibitory signal for apoptosis induction in malignant tumors.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
This disclosure belongs to the field of biomedical technology, and particularly refers to a trifunctional molecule and the application thereof. The structure of the trifunctional molecule includes a first functional domain, a second functional domain and a third functional domain. These domains are capable of simultaneously binding to CD19, CD3, and T cell positive (negative) costimulatory factors, thereby producing the first and second signal required for T cell activation. The trifunctional molecule is a recombinant protein peptide chain, which can be produced by a eukaryotic cell expression system. The product has a single structure, simple purification process, high protein yield, and preparation process and product stability. The trifunctional molecule is superior to the anti-CD19/anti-CD3 BiTE bispecific antibody in killing CD19-positive target cells. Compared with the CAR-T technology targeting CD19, the trifunctional molecule is more convenient to use, the dose is controllable, and the side effects of CAR-T are avoided.
Utilizing a computing device to assist in repurposing of a pharmaceutical. An identification of a pharmaceutical for repurposing study is received by a computing device. A pharmaceutical expression signature is retrieved based upon the identification of the pharmaceutical, the pharmaceutical expression signature indicating differential expressions of a plurality of biomolecules regulated by the pharmaceutical. A plurality of disease expression signatures are retrieved from a disease omics database, each disease expression signature indicating differential expressions of a plurality of biomolecules affected by a disease. A pharmaceutical vector is generated based upon the pharmaceutical expression signature for the pharmaceutical. A plurality of disease vectors are generated based upon the plurality of disease expression signatures for each disease. N hypotheses correlating the pharmaceutical vector and one or more of the plurality of disease vectors are generated, each hypothesis indicating a potential repurposing for the pharmaceutical to treat the disease.
BACKGROUND: Antiplatelet therapy is pivotal in endovascular treatment for intracranial aneurysms. However, there is a lack of studies comparing ticagrelor to clopidogrel in patients with aneurysms undergoing endovascular therapy. Additionally, the existing literature lacks adequate sample size, significant subgrouping, and follow-up, making our study important to cover these gaps.
METHODS: We searched 5 databases to collect all relevant studies. Categorical outcomes were pooled as relative risk (R.R.) with a 95% confidence interval (CI). In the single-arm meta-analysis, outcomes were pooled as proportions and their corresponding 95% CI.
RESULTS: This comprehensive analysis of 18 studies involving 2,427 patients. For thromboembolic events, the pooled (R.R.) did not show significant differences, whether considering overall events. A similar pattern was observed for thromboembolic events stratified by aneurysmal rupture status, with no significant differences in overall events. Hemorrhagic events did not also exhibit significant differences in previously mentioned stratifications. Furthermore, there were no substantial differences in death and mRS (0-2) on discharge between Ticagrelor and Clopidogrel. Single-arm meta-analyses for Ticagrelor demonstrated low rates of thromboembolic events, hemorrhage, death, and favorable mRS scores, with associated confidence intervals (CIs). Main line of endovascular treatment did not significantly affect either thromboembolic or hemorrhagic outcomes with Ticagrelor and Clopidogrel.
CONCLUSIONS: We found no significant differences in key outcomes like thromboembolic events, hemorrhagic events, mortality rates, and favorable mRS (0-2) upon discharge in the studied patients between Ticagrelor and Clopidogrel. Moreover, the single-arm meta-analysis for Ticagrelor revealed low rates of thromboembolic events, hemorrhage, mortality, and high rates of favorable mRS scores.
Compositions and methods of use thereof for modulating LAIR-1 are provided. For example, immunomodulatory agents are provided that reduce LAIR-1 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to increase an immune response in a subject in need thereof. Exemplary agents include (i) a soluble LAIR-2 polypeptide or fusion protein, (ii) a soluble LAIR-1 polypeptide or fusion protein, (iii) a function blocking anti-LAIR-1 antibody, (iv) an antibody that depletes LAIR-1 positive cells, and (y) combinations thereof. Immunomodulatory agents are also provided that increase LAIR-1 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to reduce an immune response in a subject in need thereof. Exemplary agents include: (i) a function activating anti-LAIR-1 antibody, (ii) a function blocking anti-LAIR-2 antibody, and (iii) a combination thereof.
The intervention arm will receive the 0.1 milliliter (mL) dose of BCG vaccine intradermally in the deltoid muscle region at the lower insertion level on the upper outer face of the right arm. When this recommendation can not be followed, the participant will be excluded from the study.
UNLABELLED: Silent sinus syndrome (SSS) is a rare condition characterized by spontaneous, progressive enophthalmos and hypophthalmos due to the collapse of the maxillary sinus, often accompanied by subclinical sinusitis.
PURPOSE: This study evaluates the clinical outcomes of treating patients with silent sinus syndrome (SSS) using a two-stage treatment approach.
MATERIAL AND METHODS: The study included 22 patients (22 eyes) with SSS who were examined at the Krasnov Research Institute of Eye Diseases between 2011 and 2023. Patients presented with complaints of enophthalmos, hypophthalmos, binocular diplopia, and decreased vision. The mean age was 36 [26; 48] years, male-to-female ratio was 6:16. All patients underwent Hertel exophthalmometry, measurement of palpebral fissure, assessment of binocular status, as well as multislice computed tomography (MSCT) of the paranasal sinuses at admission, 3 months after the first stage, and during the follow-up after the second stage of treatment. The first stage involved functional endoscopic sinus surgery (FESS), and the second stage involved correction of the eyeball position.
RESULTS: The follow-up period lasted a mean of 28 [6; 120] months. After FESS, 12 patients (12 eyes) were satisfied with the cosmetic outcome, while 10 patients (10 eyes) decided to apply for a second stage of treatment. Two patients underwent nonsurgical correction of enophthalmos with intraorbital injections, and eight underwent orbital reconstruction with implant placement. Treatment outcomes showed a significant reduction in mean value of enophthalmos (from 3.5 mm to 0.5 mm), a decrease in upper eyelid excursion compared to the contralateral side (Δ changed from 4 to 1 mm), reduction of hypophthalmos (from 2 mm to 0 mm), improvements in corneal condition and ocular motility, and regression of diplopia. No complications were registered.
CONCLUSION: Diagnosis and treatment of SSS require a multidisciplinary approach. The two-stage treatment strategy for SSS provides good functional and aesthetic outcomes.
An image storing apparatus for storing at least one image based on an image data generated by an imaging apparatus is provided. The image storing apparatus includes a receiving unit, a processor, and a storage device. The receiving unit is configured to receive the image data. The processor is configured to prepare image-relating information and prepare a data set including the image-relating information and the image data following the image-relating information. The processor prepares leading information leading to the image data as part of the image-relating information. The storage device is configured to store the data set.
Patients with NSCLC. No requirement of a specific molecular signature, but excluding known T790M mutations.